The nation of Zimbabwe has rejected a significant US healthcare agreement valued at 367 million US dollars (£272m) over five years due to the United States' demand for sensitive information.
The decision was revealed after a government memo from December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "skewed".
A government representative has since clarified that the United States was requesting health data for research and commercial purposes but was unwilling to guarantee the benefits from any future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for further talks to secure a agreement suitable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Implications
Zimbabwe's decision follows a similar case in Kenya, where a court suspended a related deal with the US after concerns were filed about the security of citizens' health data.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had managed assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral agreements to boost openness and accountability.
According to reports, 16 nations in Africa have so far signed similar health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this partnership might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Our nation was requested to provide its biological resources and data over an extended period, without any corresponding assurance of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"Effectively, our country would supply the raw materials for medical research without any assurance that the resulting innovations would be available to our people if a future health crisis emerge."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral deals were undermining structures already established through the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to manage future pandemics.
"This framework is designed to ensure that when a country provides its information, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the resources to create them."
The government's concerns regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We welcome ongoing dialogue with our American counterparts on how subsequent collaboration might be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but suggested that negotiations should continue considering a large portion of the country's Aids initiatives depended on international support.
"If specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be addressed through technical clarification and mutually agreed protections," the group added.
The situation emphasises the continuing challenges between accepting much-needed foreign assistance and safeguarding a country's data in an ever more data-driven world.